SPG3A Inhibitors
SPG3A inhibitors are a class of chemical compounds that specifically target and block the activity of SPG3A, a gene encoding the protein atlastin-1. Atlastin-1 is a dynamin-like GTPase involved in the regulation of membrane fusion, particularly in the endoplasmic reticulum (ER), where it plays a crucial role in maintaining the architecture and dynamics of the ER network. The protein is essential for ER tubule formation and the overall maintenance of ER structure, which is critical for processes like intracellular transport, protein synthesis, and lipid metabolism. By inhibiting SPG3A activity, these compounds disrupt the function of atlastin-1, leading to alterations in ER morphology and affecting intracellular processes that rely on proper ER function.
Researchers utilize SPG3A inhibitors to explore the functional roles of atlastin-1 in cellular architecture, particularly how the inhibition of SPG3A affects the organization of the ER and its related activities. Blocking SPG3A allows scientists to investigate the broader impacts of altered ER structure on cellular processes such as protein trafficking, calcium storage, and lipid homeostasis. Moreover, these inhibitors help reveal how atlastin-1 interacts with other components of the ER membrane system and the cytoskeleton to regulate membrane fusion and fission events. Studying SPG3A inhibitors sheds light on the intricate mechanisms by which cells maintain their internal membrane networks and provides insights into how disruptions in these processes can influence overall cell function and intracellular organization.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A may downregulate SPG3A expression by inhibiting histone deacetylase activity, leading to hyperacetylation of histones near the SPG3A gene promoter and repressing its transcription. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
By demethylating DNA, 5-Azacytidine could potentially decrease SPG3A expression by altering the methylation status of CpG islands within or near the SPG3A gene locus. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Suberoylanilide Hydroxamic Acid may reduce the expression of SPG3A by inhibiting histone deacetylases, resulting in chromatin remodeling that represses transcription initiation at the SPG3A gene. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $65.00 $319.00 $575.00 $998.00 | 28 | |
Retinoic acid could downregulate SPG3A by binding to retinoic acid receptors that interact with retinoic acid response elements in the promoter region of the SPG3A gene, suppressing its transcription. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin may inhibit SPG3A expression through the inactivation of the mTOR signaling pathway, which is crucial for the transcriptional initiation of many genes, including those involved in neuronal function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY 294002 could decrease SPG3A expression by inhibiting PI3K, leading to reduced phosphorylation of downstream effectors that are involved in the transcriptional regulation of the SPG3A gene. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD 98059 may inhibit SPG3A expression by blocking MEK activity, subsequently reducing ERK pathway signaling and the transcriptional activation of genes involved in neuronal development and maintenance. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 could decrease SPG3A expression by inhibiting JNK signaling, which may play a role in the transcriptional control of neuronal genes, including the SPG3A gene. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 may reduce SPG3A expression by inhibiting MEK, which could lead to a decrease in ERK-mediated transcription factor activation, thereby suppressing transcription of the SPG3A gene. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 has the potential to downregulate SPG3A expression by inhibiting p38 MAPK, which may be involved in stress-induced transcriptional responses affecting the SPG3A gene. | ||||||